Adam Sperling

Dana-Farber Cancer Inst

$1,798,495

Attributed

$1,798,495

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $465.2K · FY2020–25

$500K$375K$250K$125K$0

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$1,798,495 · 2

By mechanism

K08$1,333,340 · 1

R01$465,155 · 1

Top collaborators

No co-investigators on record.

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Novel Strategies”

Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
Mark Marino · Venturewell$48,913,644
Ted Ross · University Of Georgia$39,967,158
Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Xinhua Li · Nano Terra, Inc.$29,432,783

Research focus

Novel StrategiesHematologic NeoplasmsGenetic TranscriptionMutantResponseInnovationEpigenetic ProcessGenesInflammatoryMediatingProteinsResistancePathway InteractionsMalignant NeoplasmsAffectDysmyelopoietic SyndromesExperimental StudyCellsGrowthCareer DevelopmentCareerAdvisory CommitteesCancer CellApoptosis

Grant awards (6)

The role of SRCAP in therapy related clonal hematopoiesis$465,155

R01 · FY2025 · DK · contact PI

Defining mechanisms of thalidomide analog resistance$266,668

K08 · FY2024 · CA · contact PI

Defining mechanisms of thalidomide analog resistance$266,668

K08 · FY2023 · CA · contact PI

Defining mechanisms of thalidomide analog resistance$266,668

K08 · FY2022 · CA · contact PI

Defining mechanisms of thalidomide analog resistance$266,668

K08 · FY2021 · CA · contact PI

Defining mechanisms of thalidomide analog resistance$266,668

K08 · FY2020 · CA · contact PI